Nonalcoholic fatty liver disease: Diagnostic biomarkers

Hadizadeh, Fatemeh; Faghihimani, Elham; Adibi, Peyman

doi:10.4291/wjgp.v8.i2.11

Cited by 138 publications

(105 citation statements)

References 147 publications

(281 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this observation is not mandatory (16). The diagnostic value of ALT for NASH is still controversial and is based on unclear study results (17). In our study, the activity of ALT in rats in the HFD group is increased compared to rats in the NFD group.…”

Section: Discussionmentioning

confidence: 53%

ω-imidazolyl-alkyl derivatives as new preclinical drug candidates for NASH therapy

Diesinger¹,

Lautwein²,

Buko³

et al. 2019

Preprint

View full text Add to dashboard Cite

Cytochrome P450 2E1 (CYP2E1) and its production of ROS play an essential role in the development and progression of inflammatory liver diseases such as alcoholic steatohepatitis.For this isoenzyme we have developed two new inhibitors -12-imidazolyl-1-dodecanol (I-ol) and 1-imidazolyldodecane (I-an) -and wanted to test their effect on the related disease of non-alcoholic steatohepatitis (NASH). The fat-rich Lieber-DeCarli diet, which was administered over the entire experimental period of 16 weeks, was used for disease induction in the rat model, while the experimental substances were administered in parallel over the last four weeks. This high-calorie diet pathologically altered the ROS balance, the amount of adipocytokines, TNF-α and lipids as well as the activities of liver enzymes. Together with the histological examinations, the conclusion could be drawn that the diet led to the formation of NASH. I-ol and to a lesser extent I-an were able to shift the pathological values towards the normal range -despite continued administration of the noxious agent. I-ol, in particular, showed an extremely good tolerability in the acute toxicity study in rats. Thus, CYP2E1 appears to be a suitable drug target as well as I-ol and I-an promising drug candidates for the treatment of NASH.

show abstract

Section: Discussionmentioning

confidence: 53%

ω-imidazolyl-alkyl derivatives as new preclinical drug candidates for NASH therapy

Diesinger¹,

Lautwein²,

Buko³

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…"a" versus Control rats (Group I) and "d" versus NASH (Group VII) rats. The symbol "&, @, *" represent the statistical significance levels at p < .001, p < .01, and p < .05 accordingly hepatocyte injury releases such markers into the bloodstream and indicates the abnormality of the liver and is noticed to be elevated in rats fed with the MCD diet (Hadizadeh et al, 2017). The co-and pre-administration of the nutrient mixture to steatosis rats resulted in the decrease of all of these markers, indicating the role of the nutrient mixture as a hepatoprotective agent by reducing the damage done to the hepatocytes by other metabolic factors (Cunningham et al, 2018;Kargulewicz et al, 2014).…”

Section: F I G U R E 8 (A)mentioning

confidence: 99%

Curcuma longaandTrigonella foenum graecum‐enriched nutrient mixture from germinatedMacrotyloma uniflorumandVigna radiateameliorate nonalcoholic fatty liver diseases in rats

et al. 2020

View full text Add to dashboard Cite

The prevalence of nonalcoholic fatty liver is increasing due to modern lifestyle. Germinated and dehulled Macrotyloma uniflorum and Vigna radiate were shown to have enhanced nutrients. Curcuma longa and Trigonella foenum graecum were proven hepatoprotective.The supplementation of the nutrient herbal mixture to the MCD diet‐induced steatosis shows reduced hepatic fat accumulation and lipid profile, and liver injury markers in serum also reserved in normal. Increased serum albumin in the treatment group indicates that the liver function is enhanced than that of steatosis. The supplementation of the herbal mixture has preserved the hepatic antioxidant. Zymographic analysis of matrix metalloproteinase, western blot determination of α‐SMA, and histological evolution (H&E, Sirius red) depicted reduced fibrosis and reveled management of hepatic stellate cells in quiescent form. The present study concludes that the herbal mixture has reduced hepatocyte fat accumulation in steatotic animals, and curtailed the oxidative stress, further it prevents the progression of steatohepatitis. Practical applications Fatty liver diseases can be treated by modulating the diet composition such as consuming food rich in the nutrient herbal mixture. In this study, the nutrient mixture was made with dynamic food processing techniques such as germination, dehulling, and milling to augment the nutritional contents. Besides, Macrotyloma uniflorum, Vigna radiate, Curcuma longa, and Trigonella foenum graecum were used to improve the medicinal value and antioxidant. This formulation could target the various stages of NAFLD. This study revealed that the nutrient herbal mixture reduces the steatosis of the liver and curtailed the progression of steatohepatitis from hepatic steatosis. Since the edible foodstuff was used to make the nutrient mixture, it has excellent clinical application.

show abstract

“…Several reports have demonstrated that liver steatosis is associated with the elevation of certain clinical and biochemical markers with low predictive potential. Indeed, transaminases and specifically alanine aminotransferase (ALT) commonly used as liver damage markers are not 100% reliable because some patients suffering from NAFLD do not present high levels of ALT . Recent studies evaluating other biomarkers including circulating microRNA reported promising results, although larger studies are still necessary to validate them in the future.…”

Section: Nafld a Common Disease Affecting The Use Of Steatotic Graftmentioning

confidence: 99%

Use of Steatotic Grafts in Liver Transplantation: Current Status

et al. 2019

View full text Add to dashboard Cite

In the field of liver transplantation, the demand for adequate allografts greatly exceeds the supply. Therefore, expanding the donor pool to match the growing demand is mandatory. The present review summarizes current knowledge of the pathophysiology of ischemia/reperfusion injury in steatotic grafts, together with recent pharmacological approaches aimed at maximizing the utilization of these livers for transplantation. We also describe the preclinical models currently available to understand the molecular mechanisms controlling graft viability in this specific type of donor, critically discussing the heterogeneity in animal models, surgical methodology, and therapeutic interventions. This lack of common approaches and interventions makes it difficult to establish the pathways involved and the relevance of isolated discoveries, as well as their transferability to clinical practice. Finally, we discuss how new therapeutic strategies developed from experimental studies are promising but that further studies are warranted to translate them to the bedside.

show abstract

Nonalcoholic fatty liver disease: Diagnostic biomarkers

Cited by 138 publications

References 147 publications

ω-imidazolyl-alkyl derivatives as new preclinical drug candidates for NASH therapy

ω-imidazolyl-alkyl derivatives as new preclinical drug candidates for NASH therapy

Curcuma longaandTrigonella foenum graecum‐enriched nutrient mixture from germinatedMacrotyloma uniflorumandVigna radiateameliorate nonalcoholic fatty liver diseases in rats

Use of Steatotic Grafts in Liver Transplantation: Current Status

Contact Info

Product

Resources

About